Early intensive cholesterol-lowering study for acute coronary syndrome
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether starting strong cholesterol-lowering treatment early in the hospital can improve outcomes for people with acute coronary syndrome (a serious heart condition like a heart attack or unstable angina). It may help if you have high LDL cholesterol.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are currently in the hospital for a heart attack or unstable angina (a type of chest pain that is a warning sign for a heart attack).
- Your LDL cholesterol level is high enough: at least 1.8 mmol/L if you are already on a statin, or at least 2.6 mmol/L if you have not taken a statin in the last 4 weeks.
- You have not received a PCSK9 inhibitor (a type of cholesterol-lowering injection) in the last 3 months.
- You do not have severe liver or kidney problems, and you are not a transplant patient.
- You are not pregnant, breastfeeding, or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether starting a cholesterol-lowering drug called a PCSK9 inhibitor soon after a heart attack can help prevent future blockages. If you had a heart attack, received a stent, and have other arteries with minor blockages, this trial may be for you.
This study tests whether lowering cholesterol to very low levels (below 1.0 mmol/L) is more beneficial and safe than a slightly higher target (1.0–1.39 mmol/L) in patients with severe, recurrent heart or stroke events. You'll receive cholesterol-lowering medications and regular monitoring to see which target works best.
This study looks back at medical records of Chinese patients who had a heart attack or unstable angina. It compares outcomes for those who started a newer cholesterol-lowering shot (Alirocumab, brand name Praluent) plus a statin while in the hospital, versus those who only took a statin pill. The goal is to see if starting the shot early helps improve heart health.
This trial tests whether giving a powerful cholesterol-lowering drug (PCSK9 inhibitor) very early after a heart attack can help prevent further heart problems. It is for people who have had a recent heart attack and have blockages in more than one heart artery.
This trial studies whether starting a cholesterol-lowering medicine called a PCSK9 inhibitor early after a heart attack can improve heart health and outcomes. It focuses on people who had a recent heart-artery procedure to fix the blockage in the left anterior descending (LAD) artery.
This trial tests whether higher doses of cholesterol-lowering medication (statins) can slow down plaque buildup in the heart arteries of younger and middle-aged adults with stable chest pain. It may help prevent heart attacks and the need for procedures like stents.
Hear when a new Acute Coronary Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.